Trials that use: Risk ratio / relative risk
New to this method? Read the tutorial →
6,204 results
- Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029): primary endpoint results, effect estimate with…
- Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral Solution: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral Solution: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza Via a Human Viral Challenge Model: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza Via a Human Viral Challenge Model: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002): primary endpoint results, effect estimate with confidence…
- Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007): primary endpoint results, effect estimate with confidence interval, sample-size…
- Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016): Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid: primary endpoint results, effect estimate with…
- Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02068690).
- Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency: primary endpoint results, effect estimate with confidence interval,…
- Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 in Healthy Male Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 in Healthy Male Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03653208).
- Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2831781 After an Intravenous (IV) Dose in Healthy Japanese and Caucasian Subjects, and a Subcutaneous (SC) Dose in Healthy Caucasian Subjects: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2831781 After an Intravenous (IV) Dose in Healthy Japanese and Caucasian Subjects, and a Subcutaneous (SC) Dose in Healthy Caucasian…
- Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in Treatment-Naïve Patients With Chronic HBV Infection: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in Treatment-Naïve Patients With Chronic HBV Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer’s Disease: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese Participants: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of GSK2330811 in Healthy Japanese Participants: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of GSK2330811 in Healthy Japanese Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04138043).
- Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran: Complete Statistical AnalysisIndependent statistical analysis of Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran: primary endpoint results, effect…
- Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease: Complete Statistical AnalysisIndependent statistical analysis of Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- SAGB-PMIndependent statistical analysis of Post Implantation/Post Market Evaluation of the Swedish Adjustable Gastric Band: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00543140).
- SAGEIndependent statistical analysis of Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02539459).
- SAHA + CHOP in Untreated T-cell Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00787527).
- SAIA-HTNIndependent statistical analysis of Systems Analysis and Improvement Approach for the Hypertension Care Cascade: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04088656).
- SAILIndependent statistical analysis of Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01687179).
- Salivary Gland Surgery Before Radiation Therapy in Preventing Radiation-Caused Xerostomia in Patients With Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Salivary Gland Surgery Before Radiation Therapy in Preventing Radiation-Caused Xerostomia in Patients With Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Salsalate for Insulin Resistance in Schizophrenia: Complete Statistical AnalysisIndependent statistical analysis of Salsalate for Insulin Resistance in Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01182727).
- SALTIndependent statistical analysis of Isotonic Solution Administration Logistical Testing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02345486).
- SAMIndependent statistical analysis of Sensory Augmentation Methods in Stroke: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03988400).
- SAMMPRISIndependent statistical analysis of Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- SANDPIPERIndependent statistical analysis of A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase…
- SANICSIIIndependent statistical analysis of SANICS II Trial: Stimulation of the Autonomic Nervous System in Colorectal Surgery by Perioperative Nutrition: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly: Complete Statistical AnalysisIndependent statistical analysis of Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03312231).
- Sanofi H1N1 + TIV – Adults and Elderly: Complete Statistical AnalysisIndependent statistical analysis of Sanofi H1N1 + TIV - Adults and Elderly: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00943878).
- SAPHEIndependent statistical analysis of Somatuline Autogel Preference and Health Economy Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00681187).
- SAPPHIREIndependent statistical analysis of Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- SARONAPLUSIndependent statistical analysis of Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- SARS-CoV-2 Human Challenge Characterisation Study: Complete Statistical AnalysisIndependent statistical analysis of SARS-CoV-2 Human Challenge Characterisation Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04865237).